Page last updated: 2024-11-12

n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10324367
CHEMBL ID218394
CHEBI ID68621
SCHEMBL ID640836
MeSH IDM0500464

Synonyms (67)

Synonym
HY-10237
victrelis(tm)
boceprevir
3-azabicyclo[3.1.0]hexane-2-carboxamide, n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1r,2s,5s)-
sch503034
sch 503034
(1s,4s,5r)-n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxo-propyl]-3-[(2s)-2-(tert-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carboxamide
3-{[(1r,2s,5s)-3-[(2s)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
bdbm12311
(1r,5s)-n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(s)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(s)-carboxamide
BOC ,
victrelis
sch-503034
ebp-520
CHEMBL218394
chebi:68621 ,
ebp 520
AKOS005145787
394730-60-0
victrelis (tn)
D08876
boceprevir (inn/usan)
hsdb 8081
89bt58kelh ,
boceprevir [usan:inn]
3-azabicyclo(3.1.0)hexane-2-carboxamide, n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2s)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1r,2s,5s)-
(1r,2s,5s)-n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2s)-2-(((1,1-dimethylethyl)carbamoyl)amino)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide
unii-89bt58kelh
S3733
boceprevir & nm107
sch 503034 & nm107
(1r,2s,5s)-n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[n-(tert-butylcarbamoyl)-3-methyl-l-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CS-0361
DB08873
boceprevir [who-dd]
boceprevir [orange book]
boceprevir [vandf]
boceprevir [usan]
boceprevir [inn]
boceprevir [ema epar]
3-azabicyclo(3.1.0)hexane-2-carboxamide, n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2s)-2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-, (1r,2s,5s)-
boceprevir [mart.]
boceprevir [mi]
(1r,2s,5s)-n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[(1,1-dimethylethyl)carbamoyl]amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
(1r,2s,5s)-n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2s)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
gtpl7876
ebp520
SCHEMBL640836
J-519910
EX-A1336
mfcd22208555
ebp-520;sch503034
Q410551
(1r,2s,5s)-n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((s)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DT-0021
BCP02502
n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CCG-269852
NCGC00378631-01
DTXSID30960103
n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-{n-[(tert-butylamino)(hydroxy)methylidene]-3-methylvalyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboximidic acid
(1r,2s,5s)-n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2s)-2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide
boceprevirum
(1r,2s,5s)-n-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-(n-(tert-butylcarbamoyl)-3-methyl-l-valyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide
boceprevir (mart.)
j05ap03
EN300-7410986

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Incorporation of the P' secondary amide residue afforded significant improvement in pharmacokinetic properties."( Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan, A; Bennett, F; Bogen, SL; Chen, KX; Cheng, KC; Girijavallabhan, V; Jao, E; Njoroge, FG; Padilla, AI; Pike, RE; Saksena, AK; Sannigrahi, M; Soares, J; Tong, X; Venkatraman, S; Vibulbhan, B, 2009
)
0.35
" The HCV NS3 protease inhibitor Boceprevir (1) was reported by our research group and efforts continue for the discovery of more potent compounds with improved pharmacokinetic profiles."( Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Arasappan, A; Bennett, F; Blackman, M; Bogen, S; Cheng, KC; Hendrata, S; Huang, Y; Huelgas, R; Lovey, RG; McPhail, AT; Nair, L; Njoroge, FG; Pinto, P; Sannigrahi, M; Tong, X; Velázquez, F; Venkatraman, S, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described."( Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
Agrawal, S; Arasappan, A; Baroudy, B; Bennett, F; Bogdanowich-Knipp, S; Bogen, SL; Bradley, P; Brisson, JM; Broske, L; Butkiewicz, N; Chase, R; Chen, K; Cheng, KC; Cui, X; Ganguly, A; Girijavallabhan, V; Guo, Z; Hart, A; Hendrata, S; Hsieh, Y; Huang, Y; Ingravallo, P; Jao, E; Kong, J; Kong, R; Korfmacher, W; Liang, X; Liu, R; Liu, YT; Lovey, R; Madison, V; Malcolm, B; Njoroge, FG; Pan, W; Parekh, T; Pavlovsky, A; Pichardo, J; Pike, R; Pinto, P; Piwinski, J; Popov, V; Prelusky, D; Prongay, A; Ruan, S; Saksena, AK; Santhanam, B; Venkatraman, S; Vibulbhan, B; White, R; Wong, J; Wu, W; Yang, W, 2006
)
0.33
" Systematic optimization of different positions (P', P3, and P1) of the inhibitor resulted in the identification of the lead compound 46, which had an excellent potency (K(i)* = 4 nM, EC(90) = 30 nM) and good pharmacokinetic profile (22% and 35% bioavailability in rats and dogs, respectively)."( Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Arasappan, A; Bennett, F; Blackman, ML; Bogen, SL; Chen, KX; Cheng, KC; Nair, L; Njoroge, FG; Padilla, AI; Pan, W; Prongay, A; Shih, NY; Tong, X; Venkatraman, S; Vibulbhan, B; Yang, W, 2009
)
0.35
" Recently, we disclosed the discovery of Boceprevir, SCH 503034 (1), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that is currently undergoing phase III clinical trials."( Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan, A; Bennett, F; Bogen, SL; Chen, KX; Cheng, KC; Girijavallabhan, V; Jao, E; Njoroge, FG; Padilla, AI; Pike, RE; Saksena, AK; Sannigrahi, M; Soares, J; Tong, X; Venkatraman, S; Vibulbhan, B, 2009
)
0.35
" We recently disclosed the discovery of Boceprevir, SCH 503034 (1), which is a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been shown to be efficacious in humans and is currently undergoing clinical trials."( Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Arasappan, A; Bennett, F; Blackman, M; Bogen, S; Chen, K; Cheng, KC; George Njoroge, F; Girijavallabhan, V; Nair, L; Padilla, A; Pichardo, J; Prongay, A; Tong, X; Venkatraman, S; Wu, W, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
hepatitis C protease inhibitorAn inhibitor of hepatitis C protease, an enzyme required for production of proteins needed for viral assembly.
peptidomimeticA small protein-like chain designed to mimic a peptide.
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Ki0.01400.00000.00670.0300AID1173945
Genome polyprotein Ki0.01400.00000.00280.0200AID273218
Non-structural protein 4A Ki0.01400.00000.00670.0300AID1173945
Cathepsin L2Homo sapiens (human)IC50 (µMol)0.07500.07502.214110.0000AID508158
ProthrombinHomo sapiens (human)IC50 (µMol)1.00000.00000.710710.0000AID781217
PlasminogenHomo sapiens (human)IC50 (µMol)100.00000.02503.628010.0000AID781219
Procathepsin LHomo sapiens (human)IC50 (µMol)0.76000.00021.66619.5100AID508157
Cathepsin BHomo sapiens (human)IC50 (µMol)4.75000.00021.845310.0000AID508174; AID575659
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)42.33330.00632.073422.3780AID508161; AID575658; AID781220
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)5.91500.00402.92669.9600AID1805142; AID1805143; AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)6.80670.00022.45859.9600AID1805142; AID1805143; AID1805801; AID1845236; AID1845238; AID1861773; AID1863304; AID1863305; AID1863502; AID1884563
ChymaseHomo sapiens (human)IC50 (µMol)0.03200.02602.639710.0000AID508159
Cathepsin SHomo sapiens (human)IC50 (µMol)50.06000.00021.319110.0000AID508156; AID781218
Genome polyproteinHepatitis C virus (isolate H77)Ki0.01400.00050.00950.0140AID1796884; AID1797672
Cathepsin KHomo sapiens (human)IC50 (µMol)0.04000.00010.848210.0000AID508172
Cathepsin FHomo sapiens (human)IC50 (µMol)1.10000.79500.94751.1000AID508173
Chymotrypsin-like elastase family member 1Homo sapiens (human)IC50 (µMol)10.00000.03000.04080.0516AID508160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)1.31000.00304.45549.8200AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)5.65500.00304.11059.8200AID1805801; AID1863306
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)IC90 (µMol)1.40001.00001.20001.4000AID781217
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (156)

Processvia Protein(s)Taxonomy
apoptotic processCathepsin L2Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin L2Homo sapiens (human)
extracellular matrix disassemblyCathepsin L2Homo sapiens (human)
immune responseCathepsin L2Homo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin L2Homo sapiens (human)
positive regulation of peptidase activityCathepsin L2Homo sapiens (human)
proteolysis involved in protein catabolic processCathepsin L2Homo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
angiotensin maturationChymaseHomo sapiens (human)
peptide metabolic processChymaseHomo sapiens (human)
extracellular matrix disassemblyChymaseHomo sapiens (human)
protein catabolic processChymaseHomo sapiens (human)
midbrain developmentChymaseHomo sapiens (human)
basement membrane disassemblyChymaseHomo sapiens (human)
positive regulation of angiogenesisChymaseHomo sapiens (human)
regulation of inflammatory responseChymaseHomo sapiens (human)
cellular response to glucose stimulusChymaseHomo sapiens (human)
cytokine precursor processingChymaseHomo sapiens (human)
toll-like receptor signaling pathwayCathepsin SHomo sapiens (human)
adaptive immune responseCathepsin SHomo sapiens (human)
proteolysisCathepsin SHomo sapiens (human)
apoptotic processCathepsin SHomo sapiens (human)
response to acidic pHCathepsin SHomo sapiens (human)
protein processingCathepsin SHomo sapiens (human)
antigen processing and presentationCathepsin SHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin SHomo sapiens (human)
extracellular matrix disassemblyCathepsin SHomo sapiens (human)
collagen catabolic processCathepsin SHomo sapiens (human)
basement membrane disassemblyCathepsin SHomo sapiens (human)
antigen processing and presentation of peptide antigenCathepsin SHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin SHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin SHomo sapiens (human)
positive regulation of cation channel activityCathepsin SHomo sapiens (human)
positive regulation of peptidase activityCathepsin SHomo sapiens (human)
immune responseCathepsin SHomo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin SHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
response to nutrientAldo-keto reductase family 1 member C3Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C3Homo sapiens (human)
male gonad developmentAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to starvationAldo-keto reductase family 1 member C3Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
cyclooxygenase pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
keratinocyte differentiationAldo-keto reductase family 1 member C3Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
macromolecule metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of retinoic acid receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
renal absorptionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to calcium ionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to corticosteroid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
negative regulation of retinoic acid biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of endothelial cell apoptotic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
collagen catabolic processCathepsin KHomo sapiens (human)
mitophagyCathepsin KHomo sapiens (human)
intramembranous ossificationCathepsin KHomo sapiens (human)
proteolysisCathepsin KHomo sapiens (human)
thyroid hormone generationCathepsin KHomo sapiens (human)
apoptotic processCathepsin KHomo sapiens (human)
response to organic cyclic compoundCathepsin KHomo sapiens (human)
extracellular matrix disassemblyCathepsin KHomo sapiens (human)
collagen catabolic processCathepsin KHomo sapiens (human)
response to insulinCathepsin KHomo sapiens (human)
cellular response to zinc ion starvationCathepsin KHomo sapiens (human)
bone resorptionCathepsin KHomo sapiens (human)
response to ethanolCathepsin KHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin KHomo sapiens (human)
negative regulation of cartilage developmentCathepsin KHomo sapiens (human)
cellular response to tumor necrosis factorCathepsin KHomo sapiens (human)
cellular response to transforming growth factor beta stimulusCathepsin KHomo sapiens (human)
mononuclear cell differentiationCathepsin KHomo sapiens (human)
positive regulation of apoptotic signaling pathwayCathepsin KHomo sapiens (human)
positive regulation of peptidase activityCathepsin KHomo sapiens (human)
immune responseCathepsin KHomo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C2 Homo sapiens (human)
digestionAldo-keto reductase family 1 member C2 Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C2 Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C2 Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
proteolysisCathepsin FHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin FHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin FHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIChymotrypsin-like elastase family member 1Homo sapiens (human)
transcription by RNA polymerase IIChymotrypsin-like elastase family member 1Homo sapiens (human)
inflammatory responseChymotrypsin-like elastase family member 1Homo sapiens (human)
post-embryonic developmentChymotrypsin-like elastase family member 1Homo sapiens (human)
Wnt signaling pathwayChymotrypsin-like elastase family member 1Homo sapiens (human)
exocrine pancreas developmentChymotrypsin-like elastase family member 1Homo sapiens (human)
multicellular organism growthChymotrypsin-like elastase family member 1Homo sapiens (human)
regulation of cell population proliferationChymotrypsin-like elastase family member 1Homo sapiens (human)
regulation of cell differentiationChymotrypsin-like elastase family member 1Homo sapiens (human)
positive regulation of angiogenesisChymotrypsin-like elastase family member 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIChymotrypsin-like elastase family member 1Homo sapiens (human)
tissue remodelingChymotrypsin-like elastase family member 1Homo sapiens (human)
elastin catabolic processChymotrypsin-like elastase family member 1Homo sapiens (human)
pancreas morphogenesisChymotrypsin-like elastase family member 1Homo sapiens (human)
proteolysisChymotrypsin-like elastase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityCathepsin L2Homo sapiens (human)
serine-type endopeptidase activityCathepsin L2Homo sapiens (human)
protein bindingCathepsin L2Homo sapiens (human)
cysteine-type peptidase activityCathepsin L2Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin L2Homo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
endopeptidase activityChymaseHomo sapiens (human)
serine-type endopeptidase activityChymaseHomo sapiens (human)
serine-type peptidase activityChymaseHomo sapiens (human)
peptide bindingChymaseHomo sapiens (human)
fibronectin bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin SHomo sapiens (human)
serine-type endopeptidase activityCathepsin SHomo sapiens (human)
collagen bindingCathepsin SHomo sapiens (human)
laminin bindingCathepsin SHomo sapiens (human)
proteoglycan bindingCathepsin SHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin SHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C3Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin D2 11-ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin-F synthase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C3Homo sapiens (human)
fibronectin bindingCathepsin KHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin KHomo sapiens (human)
serine-type endopeptidase activityCathepsin KHomo sapiens (human)
protein bindingCathepsin KHomo sapiens (human)
collagen bindingCathepsin KHomo sapiens (human)
cysteine-type peptidase activityCathepsin KHomo sapiens (human)
proteoglycan bindingCathepsin KHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCathepsin KHomo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C2 Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
cysteine-type endopeptidase activityCathepsin FHomo sapiens (human)
serine-type endopeptidase activityChymotrypsin-like elastase family member 1Homo sapiens (human)
metal ion bindingChymotrypsin-like elastase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
extracellular regionCathepsin L2Homo sapiens (human)
lysosomal lumenCathepsin L2Homo sapiens (human)
extracellular spaceCathepsin L2Homo sapiens (human)
lysosomeCathepsin L2Homo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
collagen-containing extracellular matrixChymaseHomo sapiens (human)
extracellular regionChymaseHomo sapiens (human)
cytosolChymaseHomo sapiens (human)
secretory granuleChymaseHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleChymaseHomo sapiens (human)
collagen-containing extracellular matrixChymaseHomo sapiens (human)
extracellular spaceChymaseHomo sapiens (human)
intracellular membrane-bounded organelleChymaseHomo sapiens (human)
cytoplasmChymaseHomo sapiens (human)
extracellular regionCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
late endosomeCathepsin SHomo sapiens (human)
endolysosome lumenCathepsin SHomo sapiens (human)
lysosomal lumenCathepsin SHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin SHomo sapiens (human)
phagocytic vesicleCathepsin SHomo sapiens (human)
collagen-containing extracellular matrixCathepsin SHomo sapiens (human)
tertiary granule lumenCathepsin SHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin SHomo sapiens (human)
extracellular spaceCathepsin SHomo sapiens (human)
lysosomeCathepsin SHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGenome polyproteinHepatitis C virus (isolate H77)
nucleusAldo-keto reductase family 1 member C3Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular regionCathepsin KHomo sapiens (human)
extracellular spaceCathepsin KHomo sapiens (human)
nucleoplasmCathepsin KHomo sapiens (human)
lysosomeCathepsin KHomo sapiens (human)
external side of plasma membraneCathepsin KHomo sapiens (human)
apical plasma membraneCathepsin KHomo sapiens (human)
endolysosome lumenCathepsin KHomo sapiens (human)
lysosomal lumenCathepsin KHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin KHomo sapiens (human)
extracellular spaceCathepsin KHomo sapiens (human)
lysosomeCathepsin KHomo sapiens (human)
cytosolAldo-keto reductase family 1 member C2 Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
lysosomeCathepsin FHomo sapiens (human)
endoplasmic reticulumCathepsin FHomo sapiens (human)
plasma membraneCathepsin FHomo sapiens (human)
lysosomal lumenCathepsin FHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin FHomo sapiens (human)
collagen-containing extracellular matrixCathepsin FHomo sapiens (human)
extracellular exosomeCathepsin FHomo sapiens (human)
extracellular vesicleCathepsin FHomo sapiens (human)
lysosomeCathepsin FHomo sapiens (human)
extracellular spaceCathepsin FHomo sapiens (human)
extracellular spaceChymotrypsin-like elastase family member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (408)

Assay IDTitleYearJournalArticle
AID584110Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID577612Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R109K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781231Inhibition of Hepatitis C virus genotype 1b NS3/4A protease V36M mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1217480Activity of human recombinant AKR1C4 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID375714Cytotoxicity against human hepatocytes assessed as effect on GAPDH RNA level by MTS assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
AID1217444Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein afte2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577626Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1863516Binding affinity to C-terminal His tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) assessed as covalent bond formation by measuring mass adduct at 100 uM by ESI-TOF analysis
AID577377Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID410500Selectivity for human neutrophil elastase to HCV NS3 protease2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Potent inhibitors of HCV-NS3 protease derived from boronic acids.
AID1217458Drug excretion in human feces2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1726428Antiviral activity against MHV-A59 infected in Vero E6 cells assessed as reduction in viral gene expression at 100 uM treated 2 hrs post viral infection and measured after 6 hrs by RT-PCR analysis2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID577605Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 T54A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577641Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and D168A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781229Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease V36M mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID475966Selectivity for HCV NS3 protease over human neutrophil elastase2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID1217470Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID346832Bioavailability in monkey at 3 mg/kg, po administered with 0.4% hydroxypropyl methylcellulose2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
AID573109Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID577617Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577390Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q41R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781236Inhibition of Hepatitis C virus genotype 1b NS3/4A protease D168A mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID575667Apparent permeability from basolateral to apical side in human Caco2 cells2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID1071910Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID584108Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1217441Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation per mg protein afte2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217516Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 200 uM AKR inhibitor diflunisal-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577344Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36M mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577627Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID417587Cytotoxicity against human HuH7 cells2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID580574Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID508174Inhibition of human Cathepsin B2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID508183Cytotoxicity against mouse HB-1 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID1726420Antiviral activity against MHV-A59 infected in LR7 cells assessed as reduction in N protein production at 40 uM treated 2 hrs after post viral infection and measured after 6 hrs by Western blot analysis relative to control2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID577357Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R109K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577625Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168N mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID349819Bioavailability in rat at 10 mg/kg, po2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
AID577384Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577382Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80K and R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580565Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1071914Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID575658Inhibition of human leukocyte elastase after 60 mins fluorescence assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID1884564Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero 76 cells assessed as reduction in virus induced cytopathic effect measured after 5 days by neutral red uptake assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID577352Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577374Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168H mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID436458Antiviral activity against Hepatitis C virus infected in human hepatoma cell by replicon assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
AID577391Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217553Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1863504Inhibition of full length DENV2 NS2B-NS3 protease in human HeLa cells expressing luciferase reporter gene incubated for 24 hrs by luminescence analysis
AID664166Antiviral activity against wild type Hepatitis C virus subtype 1b by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1217460Drug excretion in human feces assessed as oxidative metabolites level2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577355Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577636Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577609Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580562Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID577380Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S and Q80R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID575671Clearance in dog liver microsomes2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID575652Inhibition of HCV 1b NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID577388Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36 M mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217439Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577358Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 S138T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID475968Bioavailability in rat2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID1173945Inhibition of HCV genotype 1a NS3/4A protease using Ac-DED(Edans)EEAbu-psi[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
AID711482Selectivity ratio of human elastase to HCV NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1863505Inhibition of full length DENV2 NS2B-NS3 protease in human HeLa cells expressing luciferase reporter gene at 12.5 uM incubated for 24 hrs by luminescence analysis relative to control
AID508173Inhibition of human Cathepsin F2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577349Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID369087Selectivity for HCV NS3 protease over human neutrophil elastase2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
AID781238Inhibition of Hepatitis C virus genotype 1b NS3/4A protease R155K mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577622Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781227Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease A156S mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1071919Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID273229AUC in dog at 3 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577604Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID475500AUC (0 to 24 hrs) in monkey at 3 mg/kg, po2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID346820Antiviral activity against HCV assessed as inhibition of virus replication by cell based assay in absence of human serum2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
AID577356Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577376Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID575666Apparent permeability from apical to basolateral side in human Caco2 cells2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID575663Antiviral activity against HCV 1b infected in Huh7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID417585Inhibition of full length HCV NS3/4A protease by TRF assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID577383Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217438Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID781242Inhibition of Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1726421Antiviral activity against MHV-A59 infected in LR7 cells assessed as reduction in number of infected cells at 40 uM treated 2 hrs after post viral infection and measured after 6 hrs by DAPI staining based immunofluorescence analysis relative to control2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID781228Inhibition of Hepatitis C virus genotype 1b NS3/4A protease A156S mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID349817Antiviral activity against HCV replication in human hepatoma cells by replicon assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
AID375729AUC (0 to 6 hrs) in rat at 10 mg/kg, po2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
AID456994AUC (0 to 6 hrs) in rat at 10 mg/kg, po2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID417589AUC (0 to infinity) in Wistar rat plasma at 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID1217473Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1863506Cytotoxicity against human HeLa cells expressing luciferase-based DENV-2 protease reporter system assessed as reduction in cell viability by celltiter-blue assay
AID273226AUC in monkey at 2 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577603Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1074116Antiviral activity against HCV genotype 1 infected in human assessed as cure rate2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
AID580486Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID417590Oral bioavailability in Wistar rat at 5 mg/kg2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID575655Inhibition of HCV 3a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID575661Cytotoxicity activity against human HuH7 cells by MTT assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID577361Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155Q mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577630Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID410499Inhibition of HCV subgenomic RNAs replication in human hepatoma cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Potent inhibitors of HCV-NS3 protease derived from boronic acids.
AID1071920Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1217476Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID456997AUC (0 to 6 hrs) in dog at 3 mg/kg, po2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID580567Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1071913Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID580569Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1467230Inhibition of HCV NS3/4A protease using AcDTEDVVP(Nva)-O-PAP as substrate pretreated with substrate for 3 mins followed by enzyme addition measured after 60 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
AID1161418Inhibition of Hepatitis C virus genotype 1b Con1 NS3/4A A156S mutant by FRET assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
AID577366Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID747033Cytotoxicity against human Huh7.5 cells assessed as cell viability after 48 hrs by Alamar blue assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
AID1891409Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate at 100 uM incubated for 30 mins by FRET based assay relative to control
AID1217518Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 1000 uM AKR inhibitor ibuprofen-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID273234Bioavailability in mouse2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577389Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781240Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease A156T mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID573108Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID575653Inhibition of HCV 2a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID273223Cytotoxicity against hepatoma cell line containing HCV replicon measured as change in GAPDH RNA level2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID575662Antiviral activity against HCV 1a infected in Huh7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID577613Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 S138T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577378Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V170T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781244Cytotoxicity against african green monkey Vero cells2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1217472Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217459Drug excretion in human urine2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577610Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580558Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1071915Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID508186Antiviral activity against Hepatitis C virus genotype 1b infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 10% fetal bovine serum2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID781222Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease D168A mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID508172Inhibition of human Cathepsin K2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID575665Antiviral activity against HCV 2a clone JFH1 infected in Huh7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID1726418Cytotoxicity against African green monkey Vero E6 cells assessed as maximum non-toxic concentration after 6 hrs by MTT assay2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID1217446Activity of human recombinant AKR1C2 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID508157Inhibition of human Cathepsin L2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID580487Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID781235Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease R155K mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577633Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V170T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1863305Inhibition of SARS-CoV2 BetaCoV/Wuhan/WIV04/2019 main protease expressed in Escherichia coli BL21 (DE3) cells using Dabcyl-KTSAVLQ/SGFRKME (Edans) as substrate incubated for 1 hrs by FRET-based method2022European journal of medicinal chemistry, Oct-05, Volume: 240A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
AID1845238Inhibition of SARS-CoV-2 (BetaCoV/Wuhan/WIV04/2019) MPro expressed in Escherichia coli using FRET susbtrate measured after 1 hr2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID575670Clearance in monkey liver microsomes2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID322947Antiviral activity against Hepatitis C virus infected human hepatoma cells by replicon assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID577368Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1726415Cmax in human2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID781241Inhibition of Hepatitis C virus genotype 1b NS3/4A protease A156T mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577350Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 T54A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508161Inhibition of human Neutrophil elastase 22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577360Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1726426Antiviral activity against MHV-A59 infected in Vero E6 cells assessed as reduction in viral particles at 40 nM treated 2 hrs post viral infection and measured after 6 hrs post-infection by plaque assay2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID273230Bioavailability in monkey at 2 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577623Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID575668Clearance in human liver microsomes2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID343552Inhibition of HCV NS3 serine protease2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
AID580561Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1675002Inhibition of SARS-CoV-2 main protease expressed in expressed in BL21(DE3) Escherichia Coli assessed as reduction in viral replication by FRET assay2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
The SARS-CoV-2 main protease as drug target.
AID1884563Inhibition of SARS CoV-2 BetaCoV/Wuhan/WIV04/2019 main protease expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by FRET analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID781245Cytotoxicity against human CEM cells2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID781233Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease D168V mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID781230Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease V36M mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID343554AUC in rat at 10 mg/kg, po2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
AID577372Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217485Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1173954Antiviral activity against HCV genotype 1a2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
AID577640Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80H and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217471Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1863503Inhibition of C-terminal His tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) using 2-Abz-Ser-AlaVal-Leu-Gln-Ser-Gly-Tyr(3-NO2)-Arg-OH as substrate at 50 uM preincubated for 15 mins followed by substrate addition and measured aft
AID369086Antiviral activity against HCV RNA replication in human hepatoma cells by replicon assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
AID1217530Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 100 uM AKR inhibitor diazepam-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217484Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1726419Cytotoxicity against mouse LR7 cells assessed as maximum non-toxic concentration after 6 hrs by MTT assay2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID577359Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155M mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217452Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID346819Inhibition of HCV NS3 protease in absence of human serum2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
AID580482Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID392938Inhibition of HCV isolate BK NS4A-tethered single chain NS3 serine protease2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
AID508176Inhibition of human Chymotrypsin2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577386Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and D168A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1726414Cmin in human2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID584104Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B10 harboring NS3 protease S7A, R26K, V48I, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID577614Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155M mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508185Antiviral activity against Hepatitis C virus genotype 1b infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 50% normal human serum2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577615Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577381Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580570Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580480Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1071911Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID573105Cytotoxicity against human HuH6 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID350029AUC in rat at 10 mg/kg, po2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
AID508159Inhibition of human Chymase2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID781247Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as viral RNA replication2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID475965Inhibition of HCV NS4A tagged recombinant single chain NS3 protease after 15 mins2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID475496AUC in rat at 10 mg/kg2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID573112Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID577365Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577624Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID322946Inhibition of HCV NS3 protease by FRET assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID580488Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID466502Antiviral activity against HCV replicon expressing NS3-5 infected in HuH7 cells assessed as inhibition of viral replication after 3 days by ELISA2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
AID577606Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 T54S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781223Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease V170A mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1071917Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID319955Inhibition of hepatitis C virus NS3 serine protease2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
AID575664Antiviral activity against HCV 2a infected in Huh7 cells assessed as inhibition of viral replication after 72 hrs by RT-PCR2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID584103Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b A25 harboring NS3 protease T40A, T54S, V55I, I64L, P67S, Q80K, Q88H, S90A, L153I mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID577367Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID475967Antiviral activity against HCV in human hepatoma cells assessed as inhibition of RNA replication by replicon assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID781232Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease D168V mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID577607Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID466501Inhibition of HCV NS3/4A serine protease by continuous spectrophotometric assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
AID577353Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80H mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217442Ratio of Vmax to Km for drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID475497Bioavailability in rat at 10 mg/kg2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID781217Inhibition of human thrombin2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID410498Inhibition of HCV NS3 protease assessed as hydrolysis of chromogenic 4-phenylazophenyl ester from peptide fragment Ac-DTEDVVP(Nva)-O-4-PAP by spectrophotometry2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Potent inhibitors of HCV-NS3 protease derived from boronic acids.
AID577629Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168H mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217445Ratio of Vmax to Km for drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID781218Inhibition of human cathepsin S2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID475973AUC in monkey at 3 mg/kg, po2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID577385Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80H and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577369Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID375713Antiviral activity against Hepatitis C virus genotype 1 infected in human hepatocytes by replicon assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
AID1726429Antiviral activity against MHV-A59 infected in Vero E6 cells assessed as reduction in viral gene expression at 10 uM treated 2 hrs post viral infection and measured after 6 hrs by RT-PCR analysis2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID456993Selectivity index, ratio of Ki for HNE to Ki for NS4A-tethered single chain NS3 serine protease2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID508189Inhibition of Hepatitis C virus genotype 1b NS3/4A protease activity2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID781234Inhibition of Hepatitis C virus genotype 1b NS3/4A protease D168V mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID273222Inhibition of HCV replication in hepatocytes measured by cellular replicon assay2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID1217440Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation after 60 mins by LC2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577387Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36L mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID456991Inhibition of HCV NS4A-tethered single chain NS3 serine protease assessed as Ac-DTEDVVP(Nva)- O-PAP substrate hydrolysis by spectrophotometric assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID580483Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID346833Bioavailability in dog at 3 mg/kg, po administered with 0.4% hydroxypropyl methylcellulose2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
AID508160Inhibition of human Pancreatic elastase 12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID781219Inhibition of human plasmin2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID375712Inhibition of HCV NS4A-tethered single chain NS3 serine protease by spectrophotometric assay2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
AID1726427Antiviral activity against MHV-A59 infected in Vero E6 cells assessed as reduction in viral particles at 40 nM by plaque assay2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID1217443Drug metabolism in human liver cytosol assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation after 60 mins by LC2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID584102Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID781243Cytotoxicity against human HuH7 cells2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID508184Antiviral activity against Hepatitis C virus genotype 2a infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 10% fetal bovine serum2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID575657Inhibition of HCV 6a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID1726430Antiviral activity against MHV-A59 infected in LR7 cells assessed as reduction in N protein production measured after 6 hrs by Western blot analysis relative to control2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID573111Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID577616Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155Q mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID466504AUC in rat at 10 mg/kg, po2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
AID577628Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168Y mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID473869Antiviral activity against Hepatitis C virus genotype 1 assessed as Inhibition of RNA replication transfected in human hepatoma cells2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
AID1863306Inhibition of eGFP fused SARS-CoV2 main protease transfected in HEK293T/17 cells incubated for 72 hrs by fluorescence based flow cytometry analysis2022European journal of medicinal chemistry, Oct-05, Volume: 240A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
AID580573Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID392940Antiviral activity against HCV in human Huh7 cells by replicon-based ELISA2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
AID508156Inhibition of human Cathepsin S2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID747034Antiviral activity against Hepatitis C virus subtype 2a J6/JFH transfected in human Huh7.5 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
AID781226Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease A156S mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577351Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 T54S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577635Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S and Q80R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID392942Bioavailability in rat2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
AID411320Binding affinity to HCV NS3 protease2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
AID577379Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V170A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217451Activity of human recombinant AKR1C3 expressed in HEK293 cells assessed as ratio of Vmax to Km for (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]he2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577611Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80L mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217461Drug excretion in human feces assessed as carbonyl reduction pathway related metabolites level2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID429183Antiviral activity against HCV by replicon-based cellular assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Potent aza-peptide derived inhibitors of HCV NS3 protease.
AID577346Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q41R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781224Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease V170A mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1071921Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID456992Antiviral activity against Hepatitis C virus genotype 1 by replicon assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID584101Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B13 harboring NS3 protease R26K, V46I, Q80L mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID577373Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168Y mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580571Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1678480Inhibition of recombinant C-terminal His-tagged SARS-CoV-2 main protease expressed in Escherichia coli BL21(DE3) using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 30 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID577342Antiviral activity against Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781246Cytotoxicity against human PBMC2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID580559Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID577343Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580568Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580564Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID475972AUC in rat at 10 mg/kg, po2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID577370Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168N mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID273233Bioavailability in dog at 3 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577631Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID273224AUC in rat at 10 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID577375Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508190Inhibition of Hepatitis C virus genotype 1a NS3/4A protease activity2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID1863502Inhibition of C-terminal His tagged SARS CoV-2 main protease transfected in Escherichia coli BL21 (DE3) using 2-Abz-Ser-AlaVal-Leu-Gln-Ser-Gly-Tyr(3-NO2)-Arg-OH as substrate preincubated for 15 mins followed by substrate addition and measured after 15 min
AID1726425Antiviral activity against MHV-A59 infected in LR7 cells assessed as reduction in number of infected cells at 40 nM treated 2 hrs post viral infection and measured after 6 hrs by immunofluorescence analysis2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID577362Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID580481Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1861773Inhibition of His6-tagged SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 15 mins followed by substrate addition in presence of Triton-X by FRET analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
AID575654Inhibition of HCV 2b NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID573106Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID584105Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID584106Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID273218Binding affinity at HCV NS3 protease2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID580563Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1217515Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as IC50 for AKR inhibitor diflunisal-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID508188Inhibition of Hepatitis C virus genotype 2a NS3/4A protease activity2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID1217517Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as IC50 for AKR inhibitor ibuprofen-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID375731Drug level in rat liver at 10 mg/kg, po after 8 hrs2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
AID1863304Inhibition of N-terminal recombinant SARS-CoV2 main protease expressed in Escherichia coli BL21 (DE3) cells using Dabcyl-TSAVLQ-SGFRKMK-Edans as substrate incubated for 1 hrs by fluorescence based assay2022European journal of medicinal chemistry, Oct-05, Volume: 240A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
AID575651Inhibition of HCV 1a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID664164Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156T mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID781220Inhibition of human neutrophil elastase2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1217474Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577348Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID392943Bioavailability in monkey2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
AID1217509Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID573107Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID580560Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID429184Selectivity ratio, Ki for human neutrophil elastase to Ki for HCV NS3 protease2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Potent aza-peptide derived inhibitors of HCV NS3 protease.
AID1217477Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID475499Bioavailability in monkey at 3 mg/kg2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID577371Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID573110Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID343553Antiviral activity against HCV2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
AID575659Inhibition of human CatB after 60 mins fluorescence assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID577639Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1726416Inhibition of SARS-CoV-2 3CL protease expressed in Escherichia coli BL21 DE3 using 2-aminobenzoyl-SVTLQSG-Tyr(NO2)-R as substrate preincubated with substrate for 15 mins followed by compound addition and measured after 1 hr by FRET assay2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID575669Clearance in Sprague-Dawley rat liver microsomes2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID577347Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID273221Selectivity for human neutrophil elastase (HNE) over HCV NS3 protease2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID781225Inhibition of Hepatitis C virus genotype 1b NS3/4A protease V170A mutant2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577619Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID475970Bioavailability in dog2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID273225Bioavailability in rat at 10 mg/kg, po2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID508187Inhibition of Hepatitis C virus genotype 2b NS3/4A protease activity2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID1217542Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1270705Antiviral activity against HCV genotype 1b2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates.
AID580485Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID392944Bioavailability in dog2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
AID577620Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217512Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 2 uM AKR inhibitor ritonavir-mediated metabolite formation after 60 mins co-incubated and pre-incubated with ritonavir by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID475495Antiviral activity against Hepatitis C virus infected in human hepatoma cells assessed as inhibition of viral replication2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID577608Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80H mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID411322Ratio of Ki for human neutrophil elastase to Ki for HCV NS3 protease2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
AID1726424Antiviral activity against MHV-A59 infected in LR7 cells assessed as reduction in N protein production at 4 nM treated 2 hrs post viral infection and measured after 6 hrs by Western blot analysis2020RSC medicinal chemistry, Dec-21, Volume: 12, Issue:3
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
AID580484Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID584107Ratio of EC50 for HCV1b harboring Q80K polymorphism in NS3 protease gene to EC50 for HCV1b harboring Q80Q polymorphism in NS3 protease gene2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID508158Inhibition of human Cathepsin V2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID453738Antiviral activity against HCV assessed as inhibition of viral RNA replication2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
AID1071912Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID781221Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease D168A mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1217514Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 2 uM AKR inhibitor ketoconazole-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217447Activity of human recombinant AKR1C2 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID475498AUC in monkey at 3 mg/kg2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID1217450Activity of human recombinant AKR1C3 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID369085Binding affinity to HCV NS3 protease by spectrophotometry2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
AID1071918Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID577638Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508175Inhibition of human Trypsin activity2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID417586Antiviral activity against HCV replication infected in human HuH7 cells after 72 hrs by replicon assay in presence of 5% FCS2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID577634Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V170A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID346831Bioavailability in rat at 10 mg/kg, po administered with 0.4% hydroxypropyl methylcellulose2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
AID577364Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID781239Ratio of EC90 for Hepatitis C virus genotype 1b NS3/4A protease A156T mutant to EC90 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID1217453Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217483Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID473868Inhibition of Hepatitis C virus genotype 1 NS3 protease2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
AID580572Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1217449Activity of human recombinant AKR1C3 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID319957Antiviral activity in hepatitis C virus by cell based replicon assay2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
AID1217448Activity of human recombinant AKR1C2 expressed in HEK293 cells assessed as ratio of Vmax to Km for (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]he2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217479Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1071916Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID577345Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217469Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in presenc2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID575656Inhibition of HCV 4a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID436457Inhibition of HCV NS3 protease by continuous spectrophotometric assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
AID1217478Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID349816Binding affinity to HCV NS3 protease by spectrophotometry2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
AID1217536Drug metabolism assessed as human CYP4F12-mediated compound formation from 5 to 20 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID577618Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1217481Activity of human recombinant AKR1C2 expressed in HEK293 cells assessed as (1R,2S,5S)-N-((2R,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide forma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID577354Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID411321Antiviral activity against HCV by genotype 1 replicon based cellular assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
AID1217508Drug metabolism in human liver S9 fraction at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation in pre2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID273235Ratio of drug level in liver against plasma in rat2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID475969Bioavailability in monkey2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
AID1270704Inhibition of HCV NS3/4A protease2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates.
AID577637Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80K and R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID491860Inhibition of HCV NS3 protease by FRET assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID456996AUC (0 to 6 hrs) in monkey at 10 mg/kg, po2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
AID417588Cmax in Wistar rat at 5 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
AID577621Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID475494Inhibition of HCV NS3/4A protease2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
AID453740Inhibition of HCV NS4A-tethered single chain NS3 serine protease by spectrophotometric assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
AID577632Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID584109Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID664161Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168V mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID664167Antiviral activity against Hepatitis C virus subtype 1b harboring protease R155K mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID436459Selectivity for HCV NS3 protease over human neutrophil elastase2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
AID1217482Drug metabolism in human liver cytosol at 20 uM assessed as (1R,2S,5S)-N-((2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide formation at 20 uM a2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID1217535Drug metabolism assessed as human CYP2J2-mediated compound formation from 5 to 20 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
AID429182Inhibition of HCV NS3 protease by continuous spectrophotometric assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Potent aza-peptide derived inhibitors of HCV NS3 protease.
AID580566Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID575660Binding affinity to HCV 5a NS3/4A protease2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
AID781237Ratio of EC50 for Hepatitis C virus genotype 1b NS3/4A protease R155K mutant to EC50 Hepatitis C virus genotype 1b wild type NS3/4A protease2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
AID577363Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID491861Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1805143Literature assay from Article 10.1016/j.bmcl.2021.128263: \\A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.\\2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
AID1796884Continuous Spectrophotometric Assay from Article 10.1021/jm060325b: \\Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-22006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavaila
AID1805142fluorescence resonance energy transfer (FRET)-based CoV-2 3CLpro inhibition assay from Article 10.1016/j.bmcl.2021.128263: \\A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.\\2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1797672Continuous Spectrophotometric Assay from Article 10.1021/jm060173k: \\Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,62007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (33.33)29.6817
2010's22 (43.14)24.3611
2020's12 (23.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.60 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (7.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (92.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]